Biliary tract cancer articles within Nature Communications

Featured

• Article
  07 May 2024 | Open Access

  FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

  FGFR inhibitors (FGFRi) benefit patients with FGFR2-fusion positive intrahepatic cholangiocarcinoma (ICC) but depth and duration of response is often limited. Here, the authors demonstrate that oncogenic FGFR2 signaling promotes a glycolytic phenotype, which is blocked by FGFRi, resulting in a targetable dependence on mitochondrial metabolism.

  • Yuanli Zhen
  • , Kai Liu
  •  & Nabeel Bardeesy

• Article
  12 February 2024 | Open Access

  The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

  The application of fibroblast growth factor receptor (FGFR)−2 selective tyrosine kinase inhibitors (TKIs) in cholangiocarcinoma (CCA) with FGFR2 fusions has been reported to lead to mutations in the kinase domain of FGFR2.

  Here, the authors report that non-selective TKI, lenvatinib may be an alternative in case of insurmountable side effects to specific FGFR inhibitors or to overcome and delay the development of resistance mediating FGFR2 mutations.

  • Stephan Spahn
  • , Fabian Kleinhenz
  •  & Michael Bitzer

• Article
  11 January 2024 | Open Access

  A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker

  Cholangiocarcinoma can arise anywhere within the biliary tree and is classified by anatomical locations. Here, the authors utilised RNAseq from 438 CCA patients and propose a molecular classification system independent of location.

  • Zhongqi Fan
  • , Xinchen Zou
  •  & Guoyue Lv

• Article
  11 March 2023 | Open Access

  Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

  Chemotherapeutic agents and immune checkpoint inhibitors have shown modest efficacy in patients with advanced biliary tract cancers (BTCs). Here the authors report the results of a phase II trial of the anti-PD1 antibody sintilimab plus chemotherapy (gemcitabine and cisplatin) as first-line treatment for patients with advanced BTCs.

  • Tian-mei Zeng
  • , Guang Yang
  •  & Zhen-gang Yuan

• Article
  16 January 2023 | Open Access

  Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping

  There is still need for representative models of intrahepatic cholangiocarcinoma (ICC) subtypes. Here, the authors develop organoids for two recently suggested ICC subtypes and identify distinct transcriptional profiles and potential therapeutic targets.

  • Hee Seung Lee
  • , Dai Hoon Han
  •  & Jun Yong Park

• Article
  03 December 2022 | Open Access

  Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers

  Acquired resistance can be associated with genetic changes, however, clinical molecular profiling is usually only considered at the time of diagnosis. Here, the authors use serial ctDNA profiling of 449 gastrointestinal cancers to demonstrate widespread tumour evolution associated with treatment resistance and its potential implications for treatment.

  • David Hsiehchen
  • , Leslie Bucheit
  •  & Hao Zhu

• Article
  28 March 2022 | Open Access

  Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma

  The molecular classification and tumour microenvironment in intrahepatic cholangiocarcinoma (iCCA) need further characterisation. Here, the authors perform single cell RNA-sequencing from 14 pairs of iCCA tumours and non-tumour liver tissues and propose S100P and SPP1 as markers for patient classification.

  • Guohe Song
  • , Yang Shi
  •  & Qiang Gao

• Article
  06 August 2021 | Open Access

  Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer

  The progression from biliary tract intraepithelial neoplasia (BilIN) to gallbladder carcinoma (GBC) remains unclear. Here the authors use genomics to analyze coexisting GBC lesions, low-grade and high-grade BilINs, revealing two distinct evolutionary paths for GBC development.

  • Jianzhen Lin
  • , Xinxin Peng
  •  & Han Liang

• Article
  27 July 2021 | Open Access

  GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms

  Circulating liver enzymes, like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are highly heritable and predictive of disease. Here, the authors perform a genome-wide association study on ALT and AST, revealing a rare variant in SLC30A10 associated with elevated ALT and AST.

  • Lucas D. Ward
  • , Ho-Chou Tu
  •  & Paul Nioi

• Article | 22 January 2015

  Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

  Intrahepatic cholangiocarcinoma is an aggressive cancer of the bile duct with few treatment options and a below 10% five-year survival rate. Here Sia et al. show a novel FGFR2–PPHLN1 fusion and ARAFmutations that may represent future potential therapeutic targets.

  • Daniela Sia
  • , Bojan Losic
  •  & Josep M. Llovet

• Article
  09 July 2014 | Open Access

  The Opisthorchis viverrini genome provides insights into life in the bile duct

  The Asian liver fluke is a parasitic worm that is linked to an increased risk of malignant cancer. Here, the authors sequence the draft genome and transcriptome of this fluke and provide insight into how the species has adapted to be able to survive in the bile duct.

  • Neil D. Young
  • , Niranjan Nagarajan
  •  & Robin B. Gasser